Kimberly-Clark EU Green Light And NICU Push Meet Undervalued Shares

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Kimberly-Clark and Suzano's tissue joint venture received the expected unconditional antitrust approval from the European Union. Huggies launched its "Natural Born Fighters" social impact campaign focused on supporting babies in neonatal intensive care units and their families.

For Kimberly-Clark (NasdaqGS:KMB), the fresh EU approval is a meaningful international step for its tissue partnership with Suzano, coming as the stock trades around $99.19. Over the past year, the share price shows a 22.4% decline and is 10.1% lower over five years, while the value score stands at 4, which may draw attention from investors looking at fundamentals.

The joint venture approval clarifies an important regulatory hurdle in Europe, while Huggies' "Natural Born Fighters" campaign adds a new dimension to the brand's social impact efforts. Together, these developments shape how you might think about Kimberly-Clark's global tissue platform and its long term brand positioning in baby care.

Stay updated on the most important news stories for Kimberly-Clark by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Kimberly-Clark.NasdaqGS:KMB Earnings & Revenue Growth as at May 2026

We've flagged 2 risks for Kimberly-Clark. See which could impact your investment.

Quick Assessment

✅ Price vs Analyst Target: At $99.19 versus a consensus target of $114.21, the stock trades about 13% below where analysts cluster. ✅ Simply Wall St Valuation: The shares are assessed as trading roughly 37% below estimated fair value, classed as undervalued. ✅ Recent Momentum: A 30 day return of about 2.3% signals slightly positive short term sentiment.

There is only one way to know the right time to buy, sell or hold Kimberly-Clark. Head to Simply Wall St's company report for the latest analysis of Kimberly-Clark's Fair Value.

Key Considerations

📊 EU approval reduces regulatory uncertainty around the Suzano tissue joint venture, which could matter for Kimberly-Clark's European tissue footprint. 📊 Watch how the joint venture terms, margins and any disclosed volume or capacity targets evolve, and whether the Huggies NICU campaign translates into brand strength in baby care. ⚠️ With a 5.16% dividend flagged as not well covered and a high level of debt, funding partnerships or marketing pushes without stretching the balance sheet further is an important risk to track.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Kimberly-Clark analysis. Alternatively, you can check out the community page for Kimberly-Clark to see how other investors believe this latest news will impact the company's narrative.

Story Continues

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KMB.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments